



29 March 2018

## Proteome Sciences plc

("Proteome Sciences" or the "Company")

### Notice of Results

The Directors look forward to updating shareholders on the Company's performance, and on the outlook for 2018, at the time we announce our 2017 full year results which are scheduled for release on 24 April 2018.

#### Annual General Meeting

The Annual General Meeting will take place in London during the last week of May 2018 and further details will be provided in due course.

#### For further information:

##### Proteome Sciences plc

Jeremy Haigh, Chief Executive Officer  
Ian Pike, Chief Scientific Officer

Tel: +44 (0)20 7043 2116

##### finnCap Limited (Nominated Adviser & Broker)

Geoff Nash/James Thompson  
Abigail Wayne (Broking)

Tel: +44 (0)20 7220 0500

#### About Proteome Sciences plc. ([www.proteomics.com](http://www.proteomics.com))

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant<sup>®</sup>) and for the discovery, validation and assay development of protein biomarkers (TMTcalibrator<sup>™</sup>). The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services<sup>™</sup> division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

Proteome Sciences has patented several novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.

*This announcement contains inside information for the purpose of Article 7 of EU Regulation 596/2014*